Fosamax Linked to Osteonecrosis of the Jaw: Understanding the Connection

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medication risks and benefits. Within this broad context, the dissemination of knowledge about pharmaceutical safety has evolved from basic awareness campaigns to targeted investigations of adverse effects. This heritage emphasizes the importance of translating complex biomedical data into accessible guidance for diverse populations, ensuring that individuals can make informed decisions about their therapeutic options. As the scope of health communication expands, it increasingly intersects with specialized areas of clinical concern, such as the relationship between long-term medication use and rare but serious conditions. In this continuum, the focus now shifts to a specific occupational exposure concern: the potential link between Fosamax, a bisphosphonate used for bone density management, and the development of osteonecrosis of the jaw. While general health information traditionally addresses patient populations, the transition to occupational settings highlights unique risk factors. Healthcare workers, dental professionals, and pharmaceutical manufacturing personnel may encounter heightened exposure scenarios—whether through direct patient care, handling of the drug, or environmental contact. This pivot requires a nuanced understanding of how legacy health communication frameworks can be adapted to address workplace-specific hazards, moving from population-level advisories to targeted occupational health strategies that prioritize prevention and monitoring in high-exposure environments.

Bridging General Knowledge to Specific Medical Evidence

Building on the foundation of general health communication, we now examine the specific medical evidence linking Fosamax (alendronate) to osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with ONJ, a condition characterized by exposed, non-healing bone in the maxillofacial region. This narrative examines the clinical presentation, pharmacological mechanisms, and risk considerations surrounding Fosamax and ONJ, based on available evidence.

Clinical Presentation and Risk Factors for ONJ

Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after discontinuing the drug, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Animal Model Evidence

Mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. Research using animal models has provided insights into jawbone-specific responses to bisphosphonate treatment. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate examined parameters including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). This study aimed to determine whether treatments of bisphosphonate (alendronate), parathyroid hormone, and their combination affect the jawbone, providing comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The findings suggest that altered mechanical properties and mineral density in the jawbone may contribute to the pathogenesis of ONJ.

Causation Considerations and Clinical Management

Causation considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ development. The reported onset of symptoms can occur within days to months after starting the drug, and symptoms often resolve upon discontinuation, supporting a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the similar incidence of symptoms in placebo groups in clinical trials indicates that other factors may contribute. The presence of known risk factors, such as dental procedures or comorbidities, should be assessed when determining causation. The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's labeling, which includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling describes the condition, associated risk factors, and recommendations for management, including discontinuation prior to invasive dental procedures. The timeline between exposure and documented harm varies. Symptoms may emerge rapidly, within one day, or after several months of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, discontinuation of Fosamax is recommended if severe symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a condition where bone in the jaw fails to heal after minor trauma such as tooth extraction. The risk is increased with longer use and in patients with other risk factors like dental procedures, cancer, or poor oral hygiene. Symptoms can appear within days to months of starting the drug, and discontinuation often leads to improvement.

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use.

How is ONJ diagnosed and managed in patients on Fosamax?

ONJ is diagnosed by clinical examination showing exposed bone in the jaw that does not heal within 8 weeks. Management includes discontinuation of Fosamax if severe symptoms occur, dental evaluation, and possibly antibiotic therapy or surgery. For patients requiring invasive dental procedures, temporary discontinuation of bisphosphonate may reduce risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.